Please use this identifier to cite or link to this item:
Title: A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart.
Authors: Nicholson, KG
Abrams, KR
Batham, S
Clark, TW
Hoschler, K
Lim, WS
Medina, M
Nguyen-Van-Tam, JS
Read, RC
Warren, FC
Zambon, M
First Published: Dec-2010
Citation: HEALTH TECHNOL ASSESS, 2010, 14 (55), pp. 193-334
Abstract: To evaluate the immunogenicity of a two-dose schedule of Baxter cell-cultured, non-adjuvanted, whole-virion H1N1 vaccine, and GlaxoSmithKline AS03(A)-adjuvanted split-virion H1N1 vaccine with respect to the EU Committee for Medicinal Products for Human Use (CHMP) and the US Food and Drug Administration (FDA) licensing criteria.
DOI Link: 10.3310/hta14550-04
ISSN: 1366-5278
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.